AIAISci
中文

Science community intelligence

Biotech science

Biotech league updates across protein design, genomics, cell systems, diagnostics, clinical signals, and biomanufacturing.

Reviewed signals
601
Evidence sources
721
Tracked fields
6
Biotech leagueCell and Synthetic Biology46 matching updates
clinical updateBiotecheditor reviewed
Rising signal62

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Clinical/translation signal: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Cell and Synthetic Biology
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal58

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Clinical/translation signal: Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Cell and Synthetic Biology
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal58

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Clinical/translation signal: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Cell and Synthetic Biology
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
publicationBiotecheditor reviewed
Rising signal57

L-NAME promotes foam cell formation and synthetic phenotype marker changes in vascular smooth muscle cells independent of hemodynamic effects

Publication signal: L-NAME promotes foam cell formation and synthetic phenotype marker changes in vascular smooth muscle cells independent of hemodynamic effects

Verified by AIScieditor reviewed / 1 evidence source
Cell and Synthetic Biology
1 evidence source
Source 1: Springer Science and Business Media LLC
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Tracked signal51

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Clinical/translation signal: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Cell and Synthetic Biology
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Tracked signal50

Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

Clinical/translation signal: Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Cell and Synthetic Biology
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context